473733-22-1

Basic information

• Product Name: (1R)-1-(5-METHYLFURAN-2-YL)ETHAN-1-AMINE
• Synonyms: (1R)-1-(5-METHYLFURAN-2-YL)ETHAN-1-AMINE;(R)-1-(5-Methylfuran-2-yl)ethanamine
• CAS NO: 473733-22-1
• Molecular Formula: C₇H₁₁NO
• Molecular Weight: 125.16834
• Mol File: 473733-22-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1R)-1-(5-METHYLFURAN-2-YL)ETHAN-1-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (1R)-1-(5-METHYLFURAN-2-YL)ETHAN-1-AMINE(473733-22-1)
• EPA Substance Registry System: (1R)-1-(5-METHYLFURAN-2-YL)ETHAN-1-AMINE(473733-22-1)

Safety Data

• Hazardous Substances Data: 473733-22-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(1R)-1-(5-METHYLFURAN-2-YL)ETHAN-1-AMINE is used as a chiral building block for the synthesis of various organic compounds. Its chiral nature allows for the creation of enantioenriched products, which are important in the development of pharmaceuticals and other specialty chemicals.
Used in Pharmaceutical Industry:
(1R)-1-(5-METHYLFURAN-2-YL)ETHAN-1-AMINE is used as a precursor in the development of pharmaceuticals due to its unique structure and potential biological activity. Its presence in drug molecules can contribute to specific therapeutic effects, making it a promising candidate for further research and application in medicinal chemistry.

Upstream product

• 620-02-0 5-Methylfurfural 

Relevant articles and documents

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl) propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist

Structure-activity studies on lead cyclobutenedione 3 led to the discovery of 4 (SCH 527123), a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist with excellent cell-based activity. Compound 4 displayed good oral bioavailability in rat and may be a potential therapeutic agent for the treatment of various inflammatory diseases.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.